Elebring M - Search Results

1

Understanding Statin-Roxadustat Drug-Drug-Disease Interaction Using Physiologically-Based Pharmacokinetic Modeling.

Dong J, Prieto Garcia L, Huang Y, Tang W, Lundahl A, Elebring M, Ahlström C, Vildhede A, Sjögren E, Någård M. Dong J, et al. Among authors: elebring m. Clin Pharmacol Ther. 2023 Oct;114(4):825-835. doi: 10.1002/cpt.2980. Epub 2023 Jul 13. Clin Pharmacol Ther. 2023. PMID: 37376792

2

Multiple compound-related adverse properties contribute to liver injury caused by endothelin receptor antagonists.

Kenna JG, Stahl SH, Eakins JA, Foster AJ, Andersson LC, Bergare J, Billger M, Elebring M, Elmore CS, Thompson RA. Kenna JG, et al. Among authors: elebring m. J Pharmacol Exp Ther. 2015 Feb;352(2):281-90. doi: 10.1124/jpet.114.220491. Epub 2014 Dec 2. J Pharmacol Exp Ther. 2015. PMID: 25467130

3

Effects of Tenapanor on Cytochrome P450-Mediated Drug-Drug Interactions.

Johansson S, Rosenbaum DP, Ahlqvist M, Rollison H, Knutsson M, Stefansson B, Elebring M. Johansson S, et al. Among authors: elebring m. Clin Pharmacol Drug Dev. 2017 Sep;6(5):466-475. doi: 10.1002/cpdd.346. Epub 2017 Mar 16. Clin Pharmacol Drug Dev. 2017. PMID: 28301096 Free PMC article. Clinical Trial.

4

Drug metabolism and pharmacokinetic strategies for oligonucleotide- and mRNA-based drug development.

Andersson S, Antonsson M, Elebring M, Jansson-Löfmark R, Weidolf L. Andersson S, et al. Among authors: elebring m. Drug Discov Today. 2018 Oct;23(10):1733-1745. doi: 10.1016/j.drudis.2018.05.030. Epub 2018 May 28. Drug Discov Today. 2018. PMID: 29852223 Review.

5

Corrigendum to 'Drug metabolism and pharmacokinetic strategies for oligonucleotide- and mRNA-based drug development' Drug Discovery Today 23 (2018) 1733-1745.

Andersson S, Antonsson M, Elebring M, Jansson-Löfmark R, Weidolf L. Andersson S, et al. Among authors: elebring m. Drug Discov Today. 2019 Sep;24(9):1953. doi: 10.1016/j.drudis.2018.11.025. Epub 2018 Dec 7. Drug Discov Today. 2019. PMID: 30529076 No abstract available.

6

Distribution and biotransformation of therapeutic antisense oligonucleotides and conjugates.

Weidolf L, Björkbom A, Dahlén A, Elebring M, Gennemark P, Hölttä M, Janzén D, Li X, Andersson S. Weidolf L, et al. Among authors: elebring m. Drug Discov Today. 2021 Oct;26(10):2244-2258. doi: 10.1016/j.drudis.2021.04.002. Epub 2021 Apr 20. Drug Discov Today. 2021. PMID: 33862193 Review.

7

An oral antisense oligonucleotide for PCSK9 inhibition.

Gennemark P, Walter K, Clemmensen N, Rekić D, Nilsson CAM, Knöchel J, Hölttä M, Wernevik L, Rosengren B, Kakol-Palm D, Wang Y, Yu RZ, Geary RS, Riney SJ, Monia BP, Isaksson R, Jansson-Löfmark R, Rocha CSJ, Lindén D, Hurt-Camejo E, Crooke R, Tillman L, Rydén-Bergsten T, Carlsson B, Andersson U, Elebring M, Tivesten A, Davies N. Gennemark P, et al. Among authors: elebring m. Sci Transl Med. 2021 May 12;13(593):eabe9117. doi: 10.1126/scitranslmed.abe9117. Sci Transl Med. 2021. PMID: 33980578

8

In Vivo Metabolite Profiles of an N-Acetylgalactosamine-Conjugated Antisense Oligonucleotide AZD8233 Using Liquid Chromatography High-Resolution Mass Spectrometry: A Cross-Species Comparison in Animals and Humans.

Li XQ, Elebring M, Dahlén A, Weidolf L. Li XQ, et al. Among authors: elebring m. Drug Metab Dispos. 2023 Oct;51(10):1350-1361. doi: 10.1124/dmd.123.001370. Epub 2023 Jul 10. Drug Metab Dispos. 2023. PMID: 37429729

9

Tesaglitazar, a PPARalpha/gamma agonist, induces interstitial mesenchymal cell DNA synthesis and fibrosarcomas in subcutaneous tissues in rats.

Hellmold H, Zhang H, Andersson U, Blomgren B, Holland T, Berg AL, Elebring M, Sjögren N, Bamberg K, Dahl B, Westerberg R, Dillner B, Tugwood J, Tugwood J, Roberts R, Lundholm E, Camejo G, Skånberg I, Evans J. Hellmold H, et al. Among authors: elebring m. Toxicol Sci. 2007 Jul;98(1):63-74. doi: 10.1093/toxsci/kfm094. Epub 2007 Apr 27. Toxicol Sci. 2007. PMID: 17468185

10

Pharmacokinetics and metabolism of tesaglitazar, a novel dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist, after a single oral and intravenous dose in humans.

Ericsson H, Hamrén B, Bergstrand S, Elebring M, Fryklund L, Heijer M, Ohman KP. Ericsson H, et al. Among authors: elebring m. Drug Metab Dispos. 2004 Sep;32(9):923-9. Drug Metab Dispos. 2004. PMID: 15319332 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

12 results

Search Page